Actionable insights for overcoming CMC challenges in TIL therapy: GRIT’s strategic approach

Thursday 12:00 BST / 13:00 CEST / 14:00 EEST / 14:00 EAT / 15:00 +04

Sponsor

Actionable insights for overcoming CMC challenges in TIL therapy: GRIT’s strategic approach

GRIT Biotechnology is advancing tumor-infiltrating lymphocyte (TIL) therapy as a potent treatment for solid tumors – attend this webinar for real-world insights into GRIT's approach to advancing TIL therapy development , along with a framework for evaluating novel solid tumor cell therapies based on clinical readiness, manufacturability, and scalability. 

Gain a comprehensive understanding of the current challenges in manufacturing and scaling TIL therapies for solid tumor treatment, trace the evolution of the TIL development pipeline, learn about recent advances in the field, and leave with a checklist of actionable insights for overcoming CMC hurdles in TIL production.

 Attend this webinar, sponsored by Cytiva, to learn about all stages of the TIL pipeline, including:

Bioprocess and manufacturing: understand how to streamline TIL production in the face of scale-up and regulatory complexity, with key steps for implementing flexible manufacturing strategies tailored to TIL therapies

Translational and clinical: gain an overview of emerging solutions to improve TIL viability and consistency

R&D: gain visibility of upcoming trends in solid tumor therapies, including personalized approaches and novel expansion techniques

Alex Lei

Chief Technology Officer (CTO) at GRIT Biotechnology

Dr Alex Lei is a seasoned expert in the field of solid tumor immunotherapies. He holds a PhD from the University of Southern California and currently serves as the Chief Technology Officer (CTO) at GRIT Biotechnology. Prior to this role, Dr Lei held leadership positions including CTO at TCRCure Biopharma Corp., as well as Senior Manager roles at Johnson & Johnson and Henlius Biotechnology. Over the course of his career, Dr Lei has led teams through multiple IND submissions and clinical trials targeting solid tumor interventions, demonstrating deep expertise in translational oncology and regulatory strategy.

Sabrina Carmichael

Fast Trak Global Technical Leader at Cytiva

Sabrina Carmichael is the Global Technical Leader for the Cell Therapy Fast Trak team at Cytiva. She holds a master’s degree in Biotechnology from John’s Hopkins University. Since joining Cytiva in 2017 as an R&D Scientist, she has played a role in developing innovative scientific solutions that drive the company’s impact in the life sciences sector. In 2019, Sabrina transitioned to the Fast Trak team, where she currently leads the global training program, providing hands-on, immersive training for clients and partners. This program offers comprehensive insights into Cytiva’s advanced cell therapy manufacturing platform, covering the entire end-to-end cell therapy workflow. Through her strategic guidance, the program equips customers with essential skills to harness Cytiva’s technology effectively in clinical and commercial settings. Beyond training, Sabrina directs complex process development projects, collaborating with customers to design and refine novel approaches in cell therapy manufacturing.

in 6

Days